Btw @friendlydwarves, fwiw, in 2017 ACR wrote down its Axiron IP to the tune of $10.7m. Ex this, the business would have made a net after-tax profit of $11.8m. Also in that year the business generated FCF of $4.7m. This was low due to a large tax payment in that year amounting to $6.3m - which did not match the actual tax expense for that year. The FCF before tax was $11m which well matches the P&L PBT (before IP impairments), which was $12m.
Ann: Acrux's fifth generic dossier accepted by FDA for review, page-21
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
